The process of bringing a medicine to the market is a long, difficult and costly process which takes between 10-15 years, from initial discovery in the laboratory, through the phases of clinical testing to being licensed and available on the market. Drug-Induced Liver Injury (DILI) remains the leading cause of attrition of compounds in drug development and is currently difficult to predict using in vitro cytotoxicity screening and animal studies.
The risks of ‘silent’ hepatotoxic drugs getting introduced into clinical trials, is very high garnering huge financial losses for drug companies through withdrawals and late stage clinical failures.
Our clients say
You are doing some amazing and important work at Stemnovate, we are happy to be associated with your project.
Thank you for your presentations, they were really great and stimulating. I am very happy we met and that we could get the cells in culture!
CASE STUDIES & Partnership
Prof Cliona O’Farrelly is on a mission to find out why some people…
Stemnovate and partner ANB sensors are working together as part of Liver-on-a-chip project to develop biosensors that have potential to provide microenvironment information of the cell culture systems, especially the pH measurements. The advantage is for improving the reproducibility of the cell systems and defining optimum culture conditions. ANB Sensors are also based in Cambridge […]